Compare CCC & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCC | BLLN |
|---|---|---|
| Founded | 1980 | 2016 |
| Country | United States | United States |
| Employees | 2185 | 713 |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.7B |
| IPO Year | N/A | N/A |
| Metric | CCC | BLLN |
|---|---|---|
| Price | $4.95 | $80.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | $9.44 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 9.2M | 281.7K |
| Earning Date | 04-30-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.22 | $45.96 |
| Revenue Next Year | $8.58 | $30.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.81 | $61.96 |
| 52 Week High | $8.68 | $138.70 |
| Indicator | CCC | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 29.23 | 51.76 |
| Support Level | $4.81 | $80.39 |
| Resistance Level | $6.40 | $83.20 |
| Average True Range (ATR) | 0.29 | 6.77 |
| MACD | -0.09 | 1.35 |
| Stochastic Oscillator | 3.50 | 49.68 |
CCC Intelligent Solutions Holdings Inc is a provider of cloud, mobile, AI, telematics, hyperscale technologies, and applications for the property and casualty insurance economy. The company's SaaS platform connects trading partners, facilitates commerce, and supports mission-critical, AI-enabled digital workflows. It operates in a single segment being Domestic segment, which provides SAAS platform for the P&C insurance economy and derives revenues from providing customers with software subscriptions to the platform in addition to providing professional services and non-software services. The company has its presence in the United States and China. The majority of the revenue is generated from the United States.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.